Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with Breast Cancer

Oncologist

Volumn 16, Issue 10, 2011, Pages 1458-1468

  Hamidou, Zeinab ^a,b,c   Dabakuyo, Tienhan S ^a,b,c   Mercier, Mariette ^b   Fraisse, Jean ^a   Causeret, Sylvain ^a   Tixier, Hervé ^a   Padeano, Marie Martine ^a,c   Loustalot, Catherine ^a   Cuisenier, Jean ^a   Sauzedde, Jean Marc ^d   Smail, Marc ^e   Combier, Jean Philibert ^f   Chevillote, Patrick ^f   Rosburger, Christian ^f   Arveux, Patrick ^a,c   Bonnetain, Franck ^a,b,c  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b Plateforme de Recherche Clinique Qualité de Vie et Cancer   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d Hôpital privé de Val de Saône   (France)

^e HôpitalPrivédeSainteMarie ^*  (France)

^f HÔTEL DIEU   (France)

Author keywords

Breast cancer; Longitudinal analysis; Methodology; Quality of life

Indexed keywords

HORMONE RECEPTOR;

ADULT; AGE; ARM SYMPTOMS SCORE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SYMPTOMS SCORE; CANCER ADJUVANT THERAPY; CANCER GRADING; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; GLOBAL HEALTH SCORE; HEALTH STATUS; HORMONE SUBSTITUTION; HOSPITAL; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; PATIENT ASSESSMENT; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PREMENOPAUSE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SENTINEL LYMPH NODE BIOPSY; TIME TO DETERIORATION; TUMOR CLASSIFICATION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; LYMPH NODE EXCISION; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; QUALITY OF LIFE; SENTINEL LYMPH NODE BIOPSY;

EID: 80054795810     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0085     Document Type: Article

References (22)

1. Sanders C, Egger M, Donovan J et al. Reporting on quality of life in randomised controlled trials: Bibliographic study. BMJ 1998;317:1191-1194.
2. Post WJ, Buijs C, Stolk RP et al. The analysis of longitudinal quality of life measures with informative drop-out:Apattern mixture approach. Qual Life Res 2010;19:137-148.
3. Staquet M, Berzon R, Osoba D et al. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 1996;5:496-502.
4. Osoba D, Zee B. Completion rates in health-related quality-of-life assess- ment: Approach of the National Cancer Institute of Canada Clinical Trials Group. Stat Med 1998;17:603-612.
5. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-144.
6. Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman and Hall, 2002:1-307.
7. Sprangers MA, Moinpour CM, Moynihan TJ et al. Assessing meaningful change in quality of life over time: A users' guide for clinicians. Mayo Clin Proc 2002;77:561-571.
8. Lipscomb J, Donaldson MS, Arora NK et al. Cancer outcomes research. J Natl Cancer Inst Monogr 2004;(33):178-197.
9. Dabakuyo TS, Fraisse J, Causeret S et al. A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissection. Ann Oncol 2009;20:1352-1361.
10. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
11. Sprangers MA, Schwartz CE. The challenge of response shift for qualityof- life-based clinical oncology research. Ann Oncol 1999;10:747-749.
12. Mansel RE, Fallowfield L, Kissin M et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst 2006;98:599-609.
13. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel- node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-553.
14. Purushotham AD, Upponi S, Klevesath MB et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: Results from a randomized controlled trial. J Clin Oncol 2005;23:4312-4321.
15. Bernhard J, Hr̈ny C, Maibach R et al. Quality of life as subjective experience: Reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1999;10:775-782.
16. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
17. Bonnetain F, Conroy T, Velten M et al. Impact of response shift (RS) in longitudinal post-operative quality of life (QoL) analysis among breast cancer (BC) patients: A randomized multicenter cohort study. Presented at the annual meeting of the International Society for Quality of Life Research (ISOQOL) in London, England, October 28-30, 2010.
18. Donaldson GW, Moinpour CM. Learning to live with missing quality-oflife data in advanced-stage disease trials. J Clin Oncol 2005;23:7380-7384.
19. Bonnetain F, Dahan L, Maillard E et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer 2010;46: 2753-2762.
20. Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006;24:3831-3837.
21. Ajani JA, Moiseyenko VM, Tjulandin S et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol 2007;25:3210-3216.
22. Kabbinavar FF, Wallace JF, Holmgren E et al. Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. The Oncologist 2008;13:1021-1029.